BioStock: Promore Pharma’s Q1 characterised by study progress

The reporting season is in full swing and Promore Pharma has now joined the companies that have reported on the first quarter of 2022. Published last week, the company’s report focuses primarily on the ongoing phase II study with lead candidate ensereptide. The first part of the year has been characterised by progress of the study, something that CEO Jonas Ekblom told BioStock more about.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/05/promore-pharmas-q1-characterised-by-study-progress/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se